Currently out of the existing stock ratings of Gregory Renza, 210 are a BUY (81.08%), 49 are a HOLD (18.92%).

Gregory Renza

Work Performance Price Targets & Ratings Chart

Analyst Gregory Renza, currently employed at RBC, carries an average stock price target met ratio of 37.01% that have a potential upside of 28.75% achieved within 83 days.

Gregory Renza’s has documented 509 price targets and ratings displayed on 36 stocks. The coverage is on the Healthcare sector.

Most recent stock forecast was given on VSTM, Verastem at 21-Mar-2025.

Wall Street Analyst Gregory Renza

Analyst best performing recommendations are on RXDX (PROMETHEUS BIOSCIENCES).
The best stock recommendation documented was for RXDX (PROMETHEUS BIOSCIENCES) at 12/7/2022. The price target of $111 was fulfilled within 1 day with a profit of $15.2 (15.87%) receiving and performance score of 158.66.

Average potential price target upside

ACAD ACADIA Pharmaceuticals APRE Aprea Therapeutics APTO Aptose Biosciences AVTX Avalo Therapeutics BLU BELLUS Health GMDA Gamida Cell Ltd INO Inovio Pharmaceuticals ITRM Iterum Therapeutics PLC MORF Morphic XNCR Xencor GBT Global Blood Therapeutics SGEN Seagen ADCT ADC Therapeutics SA RXDX Prometheus Biosciences VRCA Verrica Pharmaceuticals JAZZ Jazz Pharmaceuticals PLC AMGN Amgen IDYA Ideaya Biosciences LIFE aTyr Pharma NRIX Nurix Therapeutics  NUVB Nuvation Bio PRVB Provention Bio SPRB Spruce Biosciences  VIRX Viracta Therapeutics VSTM Verastem ARQL ArQule ALPN Alpine Immune Sciences CRMD CorMedix EXEL Exelixis PCRX Pacira Pharmaceuticals VRDN Viridian Therapeutics AGIO Agios Pharm BCYC Bicycle Therapeutics Ltd FULC Fulcrum Therapeutics FUSN Fusion Pharmaceuticals  JSPR Jasper Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

$20

$3.21 (19.12%)

$20

20 days ago
(07-Mar-2025)

16/21 (76.19%)

$2.39 (13.57%)

172

Buy

$27

$10.21 (60.81%)

$27

1 months ago
(27-Feb-2025)

7/21 (33.33%)

$7.66 (39.61%)

118

Buy

$28

$11.21 (66.77%)

$28

1 months ago
(27-Feb-2025)

0/6 (0%)

$8.66 (44.78%)

Buy

$28

$11.21 (66.77%)

$28

1 months ago
(27-Feb-2025)

25/37 (67.57%)

$8.66 (44.78%)

486

Hold

$22

$5.21 (31.03%)

$24

1 months 16 days ago
(11-Feb-2025)

16/21 (76.19%)

$3.51 (18.98%)

174

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Gregory Renza is most bullish on?

Potential upside of $42.61 has been obtained for IDYA (IDEAYA BIOSCIENCES)

Which stock is Gregory Renza is most reserved on?

Potential downside of -$6.14 has been obtained for PCRX (PACIRA PHARMACEUTICALS)

What Year was the first public recommendation made by Gregory Renza?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?